Cargando…
The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming
Today, cancer is understood as an epigenetic as well as genetic disease. The main epigenetic hallmarks of the cancer cell are DNA methylation and histone modifications. Proteins such as histone deacetylases (HDACs) that cause modifications of histones and other proteins can be targets for novel anti...
Autores principales: | Borutinskaitė, Veronika, Navakauskienė, Rūta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581243/ https://www.ncbi.nlm.nih.gov/pubmed/26287160 http://dx.doi.org/10.3390/ijms160818252 |
Ejemplares similares
-
Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells
por: Savickiene, Jurate, et al.
Publicado: (2012) -
Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
por: Borutinskaitė, Veronika, et al.
Publicado: (2022) -
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019) -
Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
por: Vitkevičienė, Aida, et al.
Publicado: (2020) -
Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
por: Valiulienė, Giedrė, et al.
Publicado: (2021)